GLG Network Survey: Biosimilars

Please fill out the form to request access to the survey data

SURVEY DETAILS
TARGET POPULATION

For this Network Survey, GLG surveyed 70 senior executives from pharmaceutical companies which produce biosimilars, across the US and Europe (UK, Italy, France, Germany and Spain).

What will you learn from this survey?

  • Respondents commented on the overview of the biosimilars market, including expectations on change in size of the market, demand for biosimilars, number of players in the market and consolidation.
  • The research also looked into the development and manufacturing of biosimilars including R&D challenges, approval difficulty and manufacturing preference in the industry.
  • Lastly, the survey gathered insights on the commercialization aspects of biosimilars including typical timeline for launch, market access challenges, pricing, go-to-market strategy, etc.

Examples of findings:

  • Close to half (47%) of respondents expect to see slight consolidation in the biosimilar market over the next 2 years.
  • Seven-in-ten (70%) of the respondents who declared that biosimilar producers have a background in generics, stated that it gives them a slight advantage.
  • Almost seven-in-ten (69%) respondents reported that the typical timeline for launch of biosimilars after loss of exclusivity is between 1 to 2 years.

Deliverables

The GLG Surveys team drafted the questionnaire with the support of GLG Network Member, Andrew Roberts, former Business Unit Head at Sandoz S.A.S.

  • 1 x Individual responses (“raw data”) in Excel.
  • 1 x PPT report with aggregated data.
  • Executive summary with key takeaways and highlights from the raw data.

Sample Questions

  • How do you expect the demand for biosimilars to change in the next 2 years, in your country?
  • Do you expect to see consolidation or fragmentation in the biosimilars market in the next 2 years?
  • Do you think biosimilars will eventually be seen in the same way as generics?
  • Does having a generics background give an advantage to biosimilar companies, in commercialisation of biosimilars?
  • What is the level of difficulty in getting approval for biosimilars?
  • What is the typical timeline for launch of biosimilars after the originator’s Loss of Exclusivity (LOE)?
  • What are the key market access challenges that biosimilar manufacturers currently face? Please rank the top 3, where rank 1 means the top challenge.

Access

This survey is available to subscribers of the Healthcare (HC) sector (Limited subscriptions and above). This offer includes the raw data file and a high-level presentation through PowerPoint. Please contact your GLG representative for details on your firm’s access.

DISCLAIMER

Please be advised that GLG Network Surveys operate differently than traditional GLG consultations, surveys, teleconferences, etc. and it is advisable that you consult with your firm’s legal and/or compliance department to review your use of the product and the payment for such work under your current subscription. 

By downloading this document and/or participating in the Network Survey, you understand and agree that the information and material provided by GLG, including survey results and survey proposal information, is provided for your own insight and informational purposes only. You further acknowledge and agree that this is a Network Survey for multiple GLG clients, and the results will be provided to all GLG clients that agree to participate in the Network Survey and GLG clients that agree to purchase the Survey results in the future. All survey results do not constitute investment advice or a recommendation. In using this Survey, you agree to hold Gerson Lehrman Group and the Survey respondents harmless and free of all liability as a result of your use of this Network Survey, other than liability resulting from the gross negligence or wilful misconduct of the protected party. You otherwise agree to be bound by Gerson Lehrman Group’s Usage Policies in your interactions with Gerson Lehrman Group and your receipt of services. These Survey results are for are for client’s own use and client shall not redistribute, disseminate, publish, or display the same, in whole or in part, to any third parties or publicly without the prior written permission of Gerson Lehrman Group, except explicitly set forth in your agreement with GLG. This survey will be double-blinded to both client and respondent. GLG reserves the right to restrict the number of clients that can pre-commit access. These Network Surveys are priced outside of standard GLG subscriptions but at a substantially reduced price to commissioning a fully proprietary GLG Network Survey. Upon finding these terms acceptable, please send an affirmative confirmation via email, which GLG will file in its records. Once confirmed, please note that the Client’s agreement to purchase the Network Survey is a legally binding and irrevocable commitment. If the survey is not included within your subscription, GLG will invoice Client for the fees due for the Network Survey. Please note that some respondents may not be Network Members, and the Terms and Conditions of Network Membership would not apply to such respondents and detailed records for them will not be available aside from the information that GLG capture in the Network Survey.

myGLG(ご契約企業様)
マイページ(アドバイザー様)
コンプライアンス専用ページ